Curative Biotechnology

Curative Biotechnology, Inc. (CUBT) is a publicly traded biopharmaceutical company with a mission to build a pipeline of first-in-class drugs for unmet medical needs, particularly in rare diseases. Its core strategy involves identifying, acquiring, and developing existing therapeutic candidates, thereby bypassing high-risk early discovery to accelerate development pathways. Recent achievements include securing a Canadian patent allowance and nominating a new board member with relevant expertise, as the company works to advance its preclinical and clinical-stage assets.

A business development and asset acceleration platform focused on identifying, acquiring, and developing existing therapeutic candidates, bypassing early-stage discovery to focus resources on clinical development and regulatory strategy.

Competes with numerous other biotechs and pharma companies in asset licensing and rare disease development. Differentiation relies solely on management's ability to identify and de-risk undervalued assets, a highly competitive and subjective skill.